Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of Mezigdomide and Elranatamab for relapsed/refractory multiple myeloma patients (MELTMM)
KCT0010116Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Dec 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mezigdomide, elranatamab in multiple myeloma (MM), sponsored by Pfizer. Started Dec 2024; status: recruiting.
02
Drugs
mezigdomideelranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0010116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010116.